Search Within

Katherine Marie Bell-McGuinn

Formats
  1. Meeting Abstract (32)
  2. Journal Article (27)
  3. Book Section (1)
Groups
  1. Gynecology Disease Management Team (35)
  2. Department of Medicine (34)
  3. Solid Tumor Oncology Division (34)
  4. GDMT, Medicine (32)
  5. Gynecologic Medicine Service (32)
  6. Surgery (9)

More Groups

People
  1. Carol Aghajanian (29)
  2. Jason Konner (13)
  3. Paul Sabbatini (11)
  4. William Tew (10)
  5. Martee Hensley (9)
  6. David Spriggs (8)

More People

Years
  1. 2021 (1)
  2. 2020 (5)
  3. 2019 (2)
  4. 2018 (4)
  5. 2017 (4)
  6. 2016 (4)

More Years

Publications
  1. Journal of Clinical Oncology (20)
  2. Gynecologic Oncology (15)
  3. Clinical Cancer Research (7)
  4. Cancer Research (5)
  5. Annals of Oncology (4)
  6. Diagnostic Pathology of Ovarian Tumors (1)

More Publications

Publishers
  1. American Society of Clinical Oncology (20)
  2. Elsevier Inc. (16)
  3. American Association for Cancer Research (12)
  4. Oxford University Press (4)
  5. Elsevier Science, Inc. (2)
  6. Springer (2)

More Publishers

Results (60)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Post hoc analyses of GOG 9923: Does BRCA status affect toxicities?: An NRG oncology study
    Journal Article

    Gillen, J.; Miller, A.; Bell-McGuinn, K. M.; Schilder, R. J.; Walker, J. L.; Mathews, C. A.; Duska, L. R.; Guntupalli, S. R.; O'Cearbhaill, R.; Hays, J.; more...
    Gynecologic Oncology (2021)

    Fulltext@MSK | Save
  • A phase I study of Aurora kinase A inhibitor LY3295668 erbumine as a single agent and in combination in patients with relapsed/refractory neuroblastoma
    Meeting Abstract

    DuBois, S. G.; Kremer, J. D.; De Wilde, B.; Jacobsen, C.; Aerts, I.; Mosse, Y. P.; Maris, J. M.; Lithio, A.; Gosberg, A.; Banks, C. L.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Outcomes of newly diagnosed stage II ovarian, primary peritoneal and fallopian tube cancer receiving intravenous or intraperitoneal platinum based chemotherapy in combination with veliparib and bevacizumab
    Meeting Abstract

    Washington, C. R.; Miller, A.; Moore, K. N.; Bell-McGuinn, K. M.; Schilder, R.; Walker, J. L.; Brady, W. E.; O'Cearbhaill, R. E.; Guntupalli, S. R.; Armstrong, D. K.; more...
    Gynecologic Oncology (2020)

    Fulltext@MSK | Save
  • Tolerability and adverse events experienced by women with ovarian cancer treated with intravenous or intraperitoneal chemotherapy plus veliparib and bevacizumab based on BRCA status
    Meeting Abstract

    Gillen, J.; Miller, A.; Moore, K. N.; Bell-McGuinn, K. M.; Schilder, R.; Walker, J. L.; Brady, W. E.; O'Cearbhaill, R. E.; Guntupalli, S. R.; Armstrong, D. K.; more...
    Gynecologic Oncology (2020)

    Fulltext@MSK | Save
  • Outcomes based on treatment regimen in newly diagnosed ovarian, primary peritoneal and fallopian tube cancer receiving intravenous or intraperitoneal platinum-based chemotherapy in combination with veliparib and bevacizumab
    Meeting Abstract

    Washington, C. R.; Miller, A.; Moore, K. N.; Bell-McGuinn, K. M.; Schilder, R.; Walker, J. L.; Brady, W. E.; O'Cearbhaill, R. E.; Guntupalli, S. R.; Armstrong, D. K.; more...
    Gynecologic Oncology (2020)

    Fulltext@MSK | Save
  • A phase I study of intravenous or intraperitoneal platinum based chemotherapy in combination with veliparib and bevacizumab in newly diagnosed ovarian, primary peritoneal and fallopian tube cancer
    Journal Article

    Moore, K. N.; Miller, A.; Bell-McGuinn, K. M.; Schilder, R. J.; Walker, J. L.; O'Cearbhaill, R. E.; Guntupalli, S. R.; Armstrong, D. K.; Hagemann, A. R.; Gray, H. J.; more...
    Gynecologic Oncology (2020)

    Fulltext@MSK | Save
  • Veliparib with first-line chemotherapy and as maintenance therapy in ovarian cancer
    Journal Article

    Coleman, R. L.; Fleming, G. F.; Brady, M. F.; Swisher, E. M.; Steffensen, K. D.; Friedlander, M.; Okamoto, A.; Moore, K. N.; Ben-Baruch, N. E.; Werner, T. L.; more...
    New England Journal of Medicine (2019)

    Fulltext@MSK | Save
  • A phase I study of veliparib incorporated into front-line platinum based cheotherpy and bevacizumab in epithelial ovarian cancer (NCT00989651): A GOG/nrg trial
    Meeting Abstract

    Armstrong, D. K.; Moore, K. N.; Miller, A.; Bell-McGuinn, K. M.; Schilder, R. J.; Fracasso, P. M.; Walker, J. L.; Duska, L. R.; Mathews, C. A.; Chen, A. P.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Ramucirumab (RAM) exposure-response (ER) relationship in RANGE, a randomized phase III trial of docetaxel (DOC) with or without RAM in advanced urothelial carcinoma (UC) patients (pts) who progressed on or after platinum therapy
    Meeting Abstract

    De Wit, R.; Powles, T.; Castellano, D. E.; Necchi, A.; Lee, J. L.; Van Der Heijden, M. S.; Matsubara, N.; Bamias, A.; Flechon, A.; Sternberg, C. N.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Quality-of-life (QoL) in RANGE: A phase 3 study of ramucirumab (RAM) plus docetaxel (DOC) versus placebo (P) plus DOC in platinum-refractory locally advanced or metastatic urothelial carcinoma (UC)
    Meeting Abstract

    Necchi, A.; Nishiyama, H.; Matsubara, N.; Lee, J. L.; Petrylak, D. P.; De Wit, R.; Drakaki, A.; Liepa, A. M.; Zimmermann, A.; Bell-McGuinn, K. M.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save